Neoadjuvant chemotherapy in patients with breast cancer
10.3760/cma.j.issn.1674-6090.2015.05.010
- VernacularTitle:新辅助化疗在乳腺癌手术患者中的应用
- Author:
Junping YIN
;
Dehong ZOU
- Publication Type:Journal Article
- Keywords:
Breast cancer;
Neoadjuvant chemotherapy;
Vascular endothelial growth factor;
Im-munohistochemistry
- From:
Chinese Journal of Endocrine Surgery
2015;(5):390-394
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the effect of neoadjuvant chemotherapy in patients with breast cancer , and further to explore its mechanism in order to provide a reliable basis for its clinical application .Methods 425 cases of breast cancer patients admitted from Jan .2010 to Jun.2014 were the research object , and they were divided into the control group(n=322)and the observation group(n=103).The control group received operation treatment and the observation group were added with neoadjuvant chemotherapy besides routine operation treat -ment.Incidence of clinical efficacy and adverse reactions of the 2 groups were statistically analyzed .Changes of vascular endothelial growth factor ( s-VEGF) and microvessel density ( MVD) levels before and after treatment were compared between the 2 groups.VEGF-A, the positive rate of VEGF-C and estrogen receptor(ER), progesterone receptor(PR), human epidermal growth factor receptor-2(HER2), and P53 before and after treatment were com-pared between the 2 groups.Results The total effective rate was obviously higher in the observation group than in the control group(77.7%vs 53.7%,χ2 =18.6, P<0.05).The adverse reaction rate had no statistical sig-nificance between the 2 groups(9.7% vs 5.3%, χ2 =2.57, P>0.05).s-VEGF and MVD had no statistical difference between the 2 groups before treatment(P>0.05)while they were significantly lower in the observation group than those in the control group after treatment (P<0.05).The positive rate of VEGF-A, VEGF-C, ER, PR, HER-2, and P53 had no statistical difference while they were obviously lower in the observation group than those in the control group ( P<0.05 ) .Conclusions NAC can help to improve the operation efficiency in pa-tients with breast cancer , reduce s-VEGF and MVD levels and play a role in reducing the positive rate of VEGF-A, VEGF-CER, PR, HER-2 and P53.It is an effective adjuvant treatment for breast cancer with less adverse re-actions, which is worthy of clinical application .
